{"transactions":[{"id":701801,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-29T16:18:34.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":38950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":38950,"derivative":{"exercise_price":26.88,"expiration_date":"2036-07-28","underlying":"Common Stock","underlying_shares":38950},"source":{"system":"sec-edgar","filing":"0001470831-26-000738","document":"wk-form4_1785356312.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000147083126000738/wk-form4_1785356312.xml","form_type":"4"}},{"id":713162,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-08T20:11:50.000Z","date":"2026-07-07","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in three substantially equal annual installments beginning on July 7, 2027, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":7.03,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-298542","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000119312526298542/ownership.xml","form_type":"4"}},{"id":713161,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T20:11:50.000Z","date":"2026-07-07","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit (\"RSU\") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001193125-26-298542","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000119312526298542/ownership.xml","form_type":"4"}},{"id":802174,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":222188,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F16","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F18","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":222188},"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802173,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":128565,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F16","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F18","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":128565},"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802172,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":81816,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F16","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F18","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":81816},"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802171,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14250,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F16","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F18","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802170,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":355000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.16,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":355000},"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802169,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":286000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":286000},"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802168,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":286000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":286000},"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802167,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":244000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":244000},"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802166,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":397000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":397000},"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802165,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1463134,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested.  At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.99,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":1463134},"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802164,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":808285,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents shares held by the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802163,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":300000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held by the Melissa Bender 2025 Grantor Retained Annuity Trust of which the Reporting Person's spouse is trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802162,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18197,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Represents shares held by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802161,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":147702,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802160,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":300000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held by the Jeremy Bender 2025 Grantor Retained Annuity Trust of which the Reporting Person is trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802159,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20204,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":802158,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-04-23T20:40:56.000Z","date":"2026-04-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":204643,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (\"Parent\"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the \"Company\"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the \"Merger Agreement\").  Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the \"Merger Consideration\"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001863107-26-000005","document":"form4-04232026_080451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000005/form4-04232026_080451.xml","form_type":"4"}},{"id":878502,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2026-02-27T21:30:15.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":117533,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":117533,"derivative":{"underlying":"American Depository Shares","underlying_shares":117533},"source":{"system":"sec-edgar","filing":"0001193125-26-082838","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000119312526082838/ownership.xml","form_type":"4"}},{"id":878501,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T21:30:15.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082838","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000119312526082838/ownership.xml","form_type":"4"}},{"id":898818,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-02-18T22:14:55.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":false,"shares":14812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":222188,"derivative":{"underlying":"Common Stock","underlying_shares":14812},"source":{"system":"sec-edgar","filing":"0001863107-26-000004","document":"form4-02182026_100251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000004/form4-02182026_100251.xml","form_type":"4"}},{"id":898817,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-02-18T22:14:55.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":false,"shares":11687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":128565,"derivative":{"underlying":"Common Stock","underlying_shares":11687},"source":{"system":"sec-edgar","filing":"0001863107-26-000004","document":"form4-02182026_100251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000004/form4-02182026_100251.xml","form_type":"4"}},{"id":898816,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-02-18T22:14:55.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":false,"shares":11688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":81816,"derivative":{"underlying":"Common Stock","underlying_shares":11688},"source":{"system":"sec-edgar","filing":"0001863107-26-000004","document":"form4-02182026_100251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000004/form4-02182026_100251.xml","form_type":"4"}},{"id":898815,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-02-18T22:14:55.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":false,"shares":4750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":14250,"derivative":{"underlying":"Common Stock","underlying_shares":4750},"source":{"system":"sec-edgar","filing":"0001863107-26-000004","document":"form4-02182026_100251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000004/form4-02182026_100251.xml","form_type":"4"}},{"id":898814,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-02-18T22:14:55.000Z","date":"2026-02-17","kind":"sale","planned":false,"acquired":false,"shares":15459,"price":11.6009,"value":179338.3131,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.195 to $11.8508, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":204603,"source":{"system":"sec-edgar","filing":"0001863107-26-000004","document":"form4-02182026_100251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000004/form4-02182026_100251.xml","form_type":"4"}},{"id":898813,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-02-18T22:14:55.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":true,"shares":14812,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":220102,"source":{"system":"sec-edgar","filing":"0001863107-26-000004","document":"form4-02182026_100251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000004/form4-02182026_100251.xml","form_type":"4"}},{"id":898812,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-02-18T22:14:55.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":true,"shares":11687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":205290,"source":{"system":"sec-edgar","filing":"0001863107-26-000004","document":"form4-02182026_100251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000004/form4-02182026_100251.xml","form_type":"4"}},{"id":898811,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-02-18T22:14:55.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":true,"shares":11688,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":193603,"source":{"system":"sec-edgar","filing":"0001863107-26-000004","document":"form4-02182026_100251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000004/form4-02182026_100251.xml","form_type":"4"}},{"id":898810,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-02-18T22:14:55.000Z","date":"2026-02-15","kind":"exercise","planned":false,"acquired":true,"shares":4750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":181915,"source":{"system":"sec-edgar","filing":"0001863107-26-000004","document":"form4-02182026_100251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000004/form4-02182026_100251.xml","form_type":"4"}},{"id":927483,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-01-30T22:17:49.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":237000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":237000,"derivative":{"underlying":"Common Stock","underlying_shares":237000},"source":{"system":"sec-edgar","filing":"0001863107-26-000002","document":"form4-01302026_100146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000002/form4-01302026_100146.xml","form_type":"4"}},{"id":927482,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2026-01-30T22:17:49.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":355000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":355000,"derivative":{"exercise_price":11.16,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":355000},"source":{"system":"sec-edgar","filing":"0001863107-26-000002","document":"form4-01302026_100146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310726000002/form4-01302026_100146.xml","form_type":"4"}},{"id":987998,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-26T21:10:24.000Z","date":"2025-11-25","kind":"gift","planned":false,"acquired":false,"shares":7225,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held by the Jeremy Bender 2022 Grantor Retained Annuity Trust of which the Reporting Person is trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001863107-25-000007","document":"form4-11262025_091119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000007/form4-11262025_091119.xml","form_type":"4"}},{"id":987997,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-26T21:10:24.000Z","date":"2025-11-25","kind":"gift","planned":false,"acquired":false,"shares":7225,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held by the Jeremy Bender 2022 Grantor Retained Annuity Trust of which the Reporting Person is trustee."}],"balance_after":7225,"source":{"system":"sec-edgar","filing":"0001863107-25-000007","document":"form4-11262025_091119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000007/form4-11262025_091119.xml","form_type":"4"}},{"id":987996,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-26T21:10:24.000Z","date":"2025-11-25","kind":"gift","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by the Melissa Bender 2025 Grantor Retained Annuity Trust of which the Reporting Person's spouse is trustee."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001863107-25-000007","document":"form4-11262025_091119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000007/form4-11262025_091119.xml","form_type":"4"}},{"id":987995,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-26T21:10:24.000Z","date":"2025-11-25","kind":"gift","planned":false,"acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bender Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held by the Bender Revocable Trust dated January 18, 2017."}],"balance_after":808285,"source":{"system":"sec-edgar","filing":"0001863107-25-000007","document":"form4-11262025_091119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000007/form4-11262025_091119.xml","form_type":"4"}},{"id":987994,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-26T21:10:24.000Z","date":"2025-11-25","kind":"gift","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by the Jeremy Bender 2025 Grantor Retained Annuity Trust of which the Reporting Person is trustee."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001863107-25-000007","document":"form4-11262025_091119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000007/form4-11262025_091119.xml","form_type":"4"}},{"id":987993,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-26T21:10:24.000Z","date":"2025-11-25","kind":"gift","planned":false,"acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bender Revocable Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held by the Bender Revocable Trust dated January 18, 2017."}],"balance_after":1108285,"source":{"system":"sec-edgar","filing":"0001863107-25-000007","document":"form4-11262025_091119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000007/form4-11262025_091119.xml","form_type":"4"}},{"id":996928,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-11-18T23:59:24.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":false,"shares":11687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":140252,"derivative":{"underlying":"Common Stock","underlying_shares":11687},"source":{"system":"sec-edgar","filing":"0001863107-25-000005","document":"form4-11182025_111119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000005/form4-11182025_111119.xml","form_type":"4"}},{"id":996927,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-11-18T23:59:24.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":false,"shares":11687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":93504,"derivative":{"underlying":"Common Stock","underlying_shares":11687},"source":{"system":"sec-edgar","filing":"0001863107-25-000005","document":"form4-11182025_111119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000005/form4-11182025_111119.xml","form_type":"4"}},{"id":996926,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-11-18T23:59:24.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":false,"shares":4750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":19000,"derivative":{"underlying":"Common Stock","underlying_shares":4750},"source":{"system":"sec-edgar","filing":"0001863107-25-000005","document":"form4-11182025_111119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000005/form4-11182025_111119.xml","form_type":"4"}},{"id":996925,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-11-18T23:59:24.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":false,"shares":3570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3570},"source":{"system":"sec-edgar","filing":"0001863107-25-000005","document":"form4-11182025_111119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000005/form4-11182025_111119.xml","form_type":"4"}},{"id":996924,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-18T23:59:24.000Z","date":"2025-11-17","kind":"sale","planned":false,"acquired":false,"shares":15894,"price":8.9147,"value":141690.2418,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $8.545 to $9.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":177165,"source":{"system":"sec-edgar","filing":"0001863107-25-000005","document":"form4-11182025_111119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000005/form4-11182025_111119.xml","form_type":"4"}},{"id":996923,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-18T23:59:24.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":true,"shares":11687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":193059,"source":{"system":"sec-edgar","filing":"0001863107-25-000005","document":"form4-11182025_111119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000005/form4-11182025_111119.xml","form_type":"4"}},{"id":996922,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-18T23:59:24.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":true,"shares":11687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":181372,"source":{"system":"sec-edgar","filing":"0001863107-25-000005","document":"form4-11182025_111119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000005/form4-11182025_111119.xml","form_type":"4"}},{"id":996921,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-18T23:59:24.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":true,"shares":4750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":169685,"source":{"system":"sec-edgar","filing":"0001863107-25-000005","document":"form4-11182025_111119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000005/form4-11182025_111119.xml","form_type":"4"}},{"id":996920,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-18T23:59:24.000Z","date":"2025-11-15","kind":"exercise","planned":false,"acquired":true,"shares":3570,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":164935,"source":{"system":"sec-edgar","filing":"0001863107-25-000005","document":"form4-11182025_111119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000005/form4-11182025_111119.xml","form_type":"4"}},{"id":1005362,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:16:44.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":286000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":286000,"derivative":{"exercise_price":8.99,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":286000},"source":{"system":"sec-edgar","filing":"0001863107-25-000003","document":"form4-11072025_111140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000003/form4-11072025_111140.xml","form_type":"4"}},{"id":1005361,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:16:44.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":286000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.87,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":286000},"source":{"system":"sec-edgar","filing":"0001863107-25-000003","document":"form4-11072025_111140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000003/form4-11072025_111140.xml","form_type":"4"}},{"id":1005360,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:16:44.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":286000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":286000,"derivative":{"exercise_price":8.99,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":286000},"source":{"system":"sec-edgar","filing":"0001863107-25-000003","document":"form4-11072025_111140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000003/form4-11072025_111140.xml","form_type":"4"}},{"id":1005359,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:16:44.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":286000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.44,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":286000},"source":{"system":"sec-edgar","filing":"0001863107-25-000003","document":"form4-11072025_111140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000003/form4-11072025_111140.xml","form_type":"4"}},{"id":1005358,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:16:44.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":244000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":244000,"derivative":{"exercise_price":8.99,"expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":244000},"source":{"system":"sec-edgar","filing":"0001863107-25-000003","document":"form4-11072025_111140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000003/form4-11072025_111140.xml","form_type":"4"}},{"id":1005357,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:16:44.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":244000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":23.41,"expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":244000},"source":{"system":"sec-edgar","filing":"0001863107-25-000003","document":"form4-11072025_111140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000003/form4-11072025_111140.xml","form_type":"4"}},{"id":1005356,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:16:44.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":397000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":397000,"derivative":{"exercise_price":8.99,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":397000},"source":{"system":"sec-edgar","filing":"0001863107-25-000003","document":"form4-11072025_111140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000003/form4-11072025_111140.xml","form_type":"4"}},{"id":1005355,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:16:44.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":397000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.26,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":397000},"source":{"system":"sec-edgar","filing":"0001863107-25-000003","document":"form4-11072025_111140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000003/form4-11072025_111140.xml","form_type":"4"}},{"id":1005354,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:16:44.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":1463134,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":1463134,"derivative":{"exercise_price":8.99,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":1463134},"source":{"system":"sec-edgar","filing":"0001863107-25-000003","document":"form4-11072025_111140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000003/form4-11072025_111140.xml","form_type":"4"}},{"id":1005353,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-11-07T23:16:44.000Z","date":"2025-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1463134,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the \"Repricing\") whereby the Reporting Person's options were repriced on November 6, 2025 (the \"Effective Date\") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date.  In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan (\"the Plan\"))."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan).  All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":1463134},"source":{"system":"sec-edgar","filing":"0001863107-25-000003","document":"form4-11072025_111140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000186310725000003/form4-11072025_111140.xml","form_type":"4"}},{"id":1062973,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-08-19T23:37:00.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":false,"shares":11687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":151939,"derivative":{"underlying":"Common Stock","underlying_shares":11687},"source":{"system":"sec-edgar","filing":"0001415889-25-022380","document":"form4-08192025_110856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925022380/form4-08192025_110856.xml","form_type":"4"}},{"id":1062972,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-08-19T23:37:00.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":false,"shares":11687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":105191,"derivative":{"underlying":"Common Stock","underlying_shares":11687},"source":{"system":"sec-edgar","filing":"0001415889-25-022380","document":"form4-08192025_110856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925022380/form4-08192025_110856.xml","form_type":"4"}},{"id":1062971,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-08-19T23:37:00.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":false,"shares":4750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":23750,"derivative":{"underlying":"Common Stock","underlying_shares":4750},"source":{"system":"sec-edgar","filing":"0001415889-25-022380","document":"form4-08192025_110856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925022380/form4-08192025_110856.xml","form_type":"4"}},{"id":1062970,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-08-19T23:37:00.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":false,"shares":3562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":3570,"derivative":{"underlying":"Common Stock","underlying_shares":3562},"source":{"system":"sec-edgar","filing":"0001415889-25-022380","document":"form4-08192025_110856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925022380/form4-08192025_110856.xml","form_type":"4"}},{"id":1062969,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-08-19T23:37:00.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":16058,"price":6.7671,"value":108666.0918,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $6.65 to $6.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":161365,"source":{"system":"sec-edgar","filing":"0001415889-25-022380","document":"form4-08192025_110856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925022380/form4-08192025_110856.xml","form_type":"4"}},{"id":1062968,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-08-19T23:37:00.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":true,"shares":11687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":177423,"source":{"system":"sec-edgar","filing":"0001415889-25-022380","document":"form4-08192025_110856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925022380/form4-08192025_110856.xml","form_type":"4"}},{"id":1062967,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-08-19T23:37:00.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":true,"shares":11687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":165736,"source":{"system":"sec-edgar","filing":"0001415889-25-022380","document":"form4-08192025_110856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925022380/form4-08192025_110856.xml","form_type":"4"}},{"id":1062966,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-08-19T23:37:00.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":true,"shares":4750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":154049,"source":{"system":"sec-edgar","filing":"0001415889-25-022380","document":"form4-08192025_110856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925022380/form4-08192025_110856.xml","form_type":"4"}},{"id":1062965,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-08-19T23:37:00.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":true,"shares":3562,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":149299,"source":{"system":"sec-edgar","filing":"0001415889-25-022380","document":"form4-08192025_110856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925022380/form4-08192025_110856.xml","form_type":"4"}},{"id":1088254,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-07-14T20:18:48.000Z","date":"2025-07-10","kind":"gift","planned":false,"acquired":true,"shares":179417,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bender Revocable Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"Represents an annuity payment made by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023 (\"Melissa Bender 2023 GRAT\"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by the Bender Revocable Trust dated January 18, 2017."}],"balance_after":1408285,"source":{"system":"sec-edgar","filing":"0001415889-25-019707","document":"form4-07142025_080742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925019707/form4-07142025_080742.xml","form_type":"4"}},{"id":1088253,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-07-14T20:18:48.000Z","date":"2025-07-10","kind":"gift","planned":false,"acquired":false,"shares":179417,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"Represents an annuity payment made by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023 (\"Melissa Bender 2023 GRAT\"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents shares held by the Melissa Bender 2023 GRAT."}],"balance_after":18197,"source":{"system":"sec-edgar","filing":"0001415889-25-019707","document":"form4-07142025_080742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925019707/form4-07142025_080742.xml","form_type":"4"}},{"id":1088252,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-07-14T20:18:48.000Z","date":"2024-07-02","kind":"gift","planned":false,"acquired":true,"shares":199202,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bender Revocable Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents an annuity payment made by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023 (\"Jeremy Bender 2023 GRAT\"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by the Bender Revocable Trust dated January 18, 2017."}],"balance_after":1228868,"source":{"system":"sec-edgar","filing":"0001415889-25-019707","document":"form4-07142025_080742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925019707/form4-07142025_080742.xml","form_type":"4"}},{"id":1088251,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-07-14T20:18:48.000Z","date":"2025-07-10","kind":"gift","planned":false,"acquired":false,"shares":199202,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents an annuity payment made by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023 (\"Jeremy Bender 2023 GRAT\"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held by the Jeremy Bender 2023 GRAT."}],"balance_after":20204,"source":{"system":"sec-edgar","filing":"0001415889-25-019707","document":"form4-07142025_080742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925019707/form4-07142025_080742.xml","form_type":"4"}},{"id":1088250,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-07-14T20:18:48.000Z","date":"2025-07-10","kind":"gift","planned":false,"acquired":true,"shares":74328,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bender Revocable Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents an annuity payment made by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 (\"Melissa Bender 2022 GRAT\"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by the Bender Revocable Trust dated January 18, 2017."}],"balance_after":1029666,"source":{"system":"sec-edgar","filing":"0001415889-25-019707","document":"form4-07142025_080742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925019707/form4-07142025_080742.xml","form_type":"4"}},{"id":1088249,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-07-14T20:18:48.000Z","date":"2025-07-10","kind":"gift","planned":false,"acquired":false,"shares":74328,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents an annuity payment made by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 (\"Melissa Bender 2022 GRAT\"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held by the Melissa Bender 2022 GRAT of which the Reporting Person's spouse is trustee."}],"balance_after":147702,"source":{"system":"sec-edgar","filing":"0001415889-25-019707","document":"form4-07142025_080742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925019707/form4-07142025_080742.xml","form_type":"4"}},{"id":1088248,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-07-14T20:18:48.000Z","date":"2025-07-10","kind":"gift","planned":false,"acquired":true,"shares":148312,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bender Revocable Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annuity payment made by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 (\"Jeremy Bender 2022 GRAT\"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees (\"Bender Revocable Trust dated January 18, 2017\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by the Bender Revocable Trust dated January 18, 2017."}],"balance_after":955338,"source":{"system":"sec-edgar","filing":"0001415889-25-019707","document":"form4-07142025_080742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925019707/form4-07142025_080742.xml","form_type":"4"}},{"id":1088247,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-07-14T20:18:48.000Z","date":"2025-07-10","kind":"gift","planned":false,"acquired":false,"shares":148312,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annuity payment made by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 (\"Jeremy Bender 2022 GRAT\"), which was transferred by the Reporting Person as a bona fide gift for no consideration to the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees (\"Bender Revocable Trust dated January 18, 2017\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by the Jeremy Bender 2022 GRAT of which the Reporting Person is trustee."}],"balance_after":14450,"source":{"system":"sec-edgar","filing":"0001415889-25-019707","document":"form4-07142025_080742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925019707/form4-07142025_080742.xml","form_type":"4"}},{"id":1143993,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-05-19T21:44:25.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":false,"shares":11687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":163626,"derivative":{"underlying":"Common Stock","underlying_shares":11687},"source":{"system":"sec-edgar","filing":"0001415889-25-013676","document":"form4-05192025_090520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925013676/form4-05192025_090520.xml","form_type":"4"}},{"id":1143992,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-05-19T21:44:25.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":false,"shares":11687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":116878,"derivative":{"underlying":"Common Stock","underlying_shares":11687},"source":{"system":"sec-edgar","filing":"0001415889-25-013676","document":"form4-05192025_090520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925013676/form4-05192025_090520.xml","form_type":"4"}},{"id":1143991,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-05-19T21:44:25.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":false,"shares":4750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":28500,"derivative":{"underlying":"Common Stock","underlying_shares":4750},"source":{"system":"sec-edgar","filing":"0001415889-25-013676","document":"form4-05192025_090520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925013676/form4-05192025_090520.xml","form_type":"4"}},{"id":1143990,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-05-19T21:44:25.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":false,"shares":3562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":7132,"derivative":{"underlying":"Common Stock","underlying_shares":3562},"source":{"system":"sec-edgar","filing":"0001415889-25-013676","document":"form4-05192025_090520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925013676/form4-05192025_090520.xml","form_type":"4"}},{"id":1143989,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-05-19T21:44:25.000Z","date":"2025-05-16","kind":"sale","planned":false,"acquired":false,"shares":13964,"price":6.2579,"value":87385.3156,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $6.19 to $6.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":145737,"source":{"system":"sec-edgar","filing":"0001415889-25-013676","document":"form4-05192025_090520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925013676/form4-05192025_090520.xml","form_type":"4"}},{"id":1143988,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-05-19T21:44:25.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":true,"shares":11687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":159701,"source":{"system":"sec-edgar","filing":"0001415889-25-013676","document":"form4-05192025_090520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925013676/form4-05192025_090520.xml","form_type":"4"}},{"id":1143987,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-05-19T21:44:25.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":true,"shares":11687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":148014,"source":{"system":"sec-edgar","filing":"0001415889-25-013676","document":"form4-05192025_090520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925013676/form4-05192025_090520.xml","form_type":"4"}},{"id":1143986,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-05-19T21:44:25.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":true,"shares":4750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":136327,"source":{"system":"sec-edgar","filing":"0001415889-25-013676","document":"form4-05192025_090520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925013676/form4-05192025_090520.xml","form_type":"4"}},{"id":1143985,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-05-19T21:44:25.000Z","date":"2025-05-15","kind":"exercise","planned":false,"acquired":true,"shares":3562,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":131577,"source":{"system":"sec-edgar","filing":"0001415889-25-013676","document":"form4-05192025_090520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925013676/form4-05192025_090520.xml","form_type":"4"}},{"id":1254208,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-02-21T23:05:43.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":false,"shares":11687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":175313,"derivative":{"underlying":"Common Stock","underlying_shares":11687},"source":{"system":"sec-edgar","filing":"0001415889-25-005154","document":"form4-02212025_110239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925005154/form4-02212025_110239.xml","form_type":"4"}},{"id":1254207,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-02-21T23:05:43.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":false,"shares":11687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":128565,"derivative":{"underlying":"Common Stock","underlying_shares":11687},"source":{"system":"sec-edgar","filing":"0001415889-25-005154","document":"form4-02212025_110239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925005154/form4-02212025_110239.xml","form_type":"4"}},{"id":1254206,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-02-21T23:05:43.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":false,"shares":4750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":33250,"derivative":{"underlying":"Common Stock","underlying_shares":4750},"source":{"system":"sec-edgar","filing":"0001415889-25-005154","document":"form4-02212025_110239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925005154/form4-02212025_110239.xml","form_type":"4"}},{"id":1254205,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2025-02-21T23:05:43.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":false,"shares":3562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":10694,"derivative":{"underlying":"Common Stock","underlying_shares":3562},"source":{"system":"sec-edgar","filing":"0001415889-25-005154","document":"form4-02212025_110239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925005154/form4-02212025_110239.xml","form_type":"4"}},{"id":1254204,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-02-21T23:05:43.000Z","date":"2025-02-18","kind":"sale","planned":false,"acquired":false,"shares":12048,"price":11.963,"value":144130.224,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.86 to $12.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade."}],"balance_after":128015,"source":{"system":"sec-edgar","filing":"0001415889-25-005154","document":"form4-02212025_110239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925005154/form4-02212025_110239.xml","form_type":"4"}},{"id":1254203,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-02-21T23:05:43.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":true,"shares":11687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":140063,"source":{"system":"sec-edgar","filing":"0001415889-25-005154","document":"form4-02212025_110239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925005154/form4-02212025_110239.xml","form_type":"4"}},{"id":1254202,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-02-21T23:05:43.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":true,"shares":11687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":128376,"source":{"system":"sec-edgar","filing":"0001415889-25-005154","document":"form4-02212025_110239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925005154/form4-02212025_110239.xml","form_type":"4"}},{"id":1254201,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-02-21T23:05:43.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":true,"shares":4750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":116689,"source":{"system":"sec-edgar","filing":"0001415889-25-005154","document":"form4-02212025_110239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925005154/form4-02212025_110239.xml","form_type":"4"}},{"id":1254200,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-02-21T23:05:43.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":true,"shares":3562,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":111939,"source":{"system":"sec-edgar","filing":"0001415889-25-005154","document":"form4-02212025_110239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925005154/form4-02212025_110239.xml","form_type":"4"}},{"id":1280813,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2025-02-06T21:30:14.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":16768,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":16768,"derivative":{"underlying":"American Depository Shares","underlying_shares":16768},"source":{"system":"sec-edgar","filing":"0000950170-25-015433","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000095017025015433/ownership.xml","form_type":"4"}},{"id":1280812,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T21:30:14.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015433","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000095017025015433/ownership.xml","form_type":"4"}},{"id":1290106,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-01-31T21:36:18.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":187000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":187000,"derivative":{"underlying":"Common Stock","underlying_shares":187000},"source":{"system":"sec-edgar","filing":"0001415889-25-002491","document":"form4-01312025_090113.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925002491/form4-01312025_090113.xml","form_type":"4"}},{"id":1290105,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-01-31T21:36:18.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":286000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":286000,"derivative":{"exercise_price":11.87,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":286000},"source":{"system":"sec-edgar","filing":"0001415889-25-002491","document":"form4-01312025_090113.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588925002491/form4-01312025_090113.xml","form_type":"4"}},{"id":1360407,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-11-19T21:36:19.000Z","date":"2024-11-15","kind":"exercise","planned":false,"acquired":false,"shares":11687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":140252,"derivative":{"underlying":"Common Stock","underlying_shares":11687},"source":{"system":"sec-edgar","filing":"0001415889-24-027239","document":"form4-11192024_091115.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588924027239/form4-11192024_091115.xml","form_type":"4"}},{"id":1360406,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-11-19T21:36:19.000Z","date":"2024-11-15","kind":"exercise","planned":false,"acquired":false,"shares":4750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":38000,"derivative":{"underlying":"Common Stock","underlying_shares":4750},"source":{"system":"sec-edgar","filing":"0001415889-24-027239","document":"form4-11192024_091115.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588924027239/form4-11192024_091115.xml","form_type":"4"}},{"id":1360405,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2024-11-19T21:36:19.000Z","date":"2024-11-15","kind":"exercise","planned":false,"acquired":false,"shares":3562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"RSUs do not expire; they either vest or are canceled prior to the vesting date."}],"balance_after":14256,"derivative":{"underlying":"Common Stock","underlying_shares":3562},"source":{"system":"sec-edgar","filing":"0001415889-24-027239","document":"form4-11192024_091115.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000141588924027239/form4-11192024_091115.xml","form_type":"4"}}],"next_cursor":"2024-11-19T21:36:19.000000Z,1360405"}